On August 31, 2023, ProMIS Neurosciences, Inc., closed the transaction. The company issued 9,945,969 common share at a price of $1.88 per unit consisting of one common share and one warrant and 954,725 pre-funded units at a price of $1.87 per unit consisting of one pre-funded warrant for the gross proceeds of $20.4 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.96 USD | -1.26% | -1.01% | +70.43% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+70.43% | 37.16M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- PMN Stock
- News ProMIS Neurosciences, Inc.
- ProMIS Neurosciences, Inc. announced that it has received $20.483758 million in funding from Affinity Asset Advisors, LLC, Ally Bridge Group, Sphera Healthcare US Inc.